Can biofeedback-based videogames help children better manage stress? Magellan Health and Mightier secure $2 million NIMH grant to investigate

Might­i­er and Mag­el­lan Health Launch NIMH-Fund­ed Research to Improve Out­comes in Chil­dren’s Men­tal Health through the Use of Video Games (press release): Might­i­er, provider of a ground-break­ing video game sys­tem for teach­ing chil­dren emo­tion­al reg­u­la­tion, today announced the com­pa­ny has been award­ed a $2 mil­lion grant from the Nation­al Insti­tute of Men­tal Health (NIMH) to…

Read More

Neuromodulation device Relivion gets FDA clearance to help patients with major depression who don’t benefit from antidepressant medications

Neu­rolief wins FDA break­through nod for wear­able neu­ro­mod for depres­sion (Mass Device): Neu­rolief announced today that it received FDA break­through device des­ig­na­tion for its Reliv­ion DP sys­tem for treat­ing major depres­sion. Reliv­ion is a wear­able, non-inva­­sive, mul­ti-chan­nel brain neu­ro­mod­u­la­tion device designed as an adjunc­tive treat­ment to phar­ma­ceu­ti­cal man­age­ment of major depres­sive dis­or­der (MDD) in adults…

Read More

Magellan Health is testing biofeedback videogame Mightier to help children better self-regulate stress and behavioral health

Mag­el­lan Health pilot­ing Might­ier’s video game plat­form for emo­tion­al reg­u­la­tion train­ing (Mobi­Health­News): Scotts­dale, Ari­­zona-based Mag­el­lan Health announced today that it has launched a pilot of Boston Chil­dren’s Hos­pi­tal spin-out Neu­ro­mo­tion Labs’ Might­i­er, a biofeed­back video game plat­form designed to help chil­dren reg­u­late their emotions.

Read More

Update: Common anticholinergic meds seen to increase dementia risk

________________ Dear read­er, It’s time for Sharp­Brains e‑newsletter dis­cussing the lat­est research and inno­va­tions to help pro­mote brain health, open­ing in this occa­sion with a large and wor­ry­ing study track­ing the long-term neur­al impact of com­mon­ly pre­scribed med­ica­tions. New brain research: First, do no harm? Com­mon anti­cholin­er­gic meds seen to increase demen­tia risk …which is one…

Read More